CICC International: Upgraded target on Sino Biopharmaceutical (01801.HK) to 100 Hong Kong dollars, maintaining "outperform" rating.

Zhixin Finance APP learned that CCB International released a research report stating that Sino Biopharmaceutical (01801.HK) has short-term catalysts including potential out-of-China external authorization, as well as positive clinical results for the company's key clinical-stage drugs; the company was listed as the industry's top pick, with the target price raised from 90 Hong Kong dollars to 100 Hong Kong dollars, and maintaining an "outperform the market" rating.